Dr. Amos’ specific areas of patent procurement include artificial intelligence-based technologies, diagnostic technologies, antibodies and fusion proteins, engineered immune therapeutics and targeted therapies, immune checkpoint interventions, recombinant live vaccines, vaccine enhancers, cancer therapies, nucleic acid sequencing technologies, siRNAs, antisense oligonucleotides, nucleic acid-based nanotechnologies, stem cell-based therapies, cardiac treatments, neurological therapies & rehabilitative interventions, EEG-based methods, medical devices, small molecules, pharmaceutical formulations, complete syntheses of natural products, biosensors, and lithium ion batteries & separators.
Dr. Amos has published articles in Nature Biotechnology and Oxford University Press on patent law issues and has been a webinar presenter to Tech Transfer professionals and other attorneys on subjects such as patentable subject matter in diagnostics, Bayh-Dole Act compliance, and university data policies & protection.
Because Dr. Amos works alongside patent litigators, his approach to patent prosecution is keenly formed by knowledge of how a patent may be challenged. In addition to having broad experience in all aspects of U.S. patent procurement, including ex-parte PTAB appeals, IPR, PGR, reissue, reexamination, and interference practice, he has extensive experience in international prosecution including before the European, Japanese, Chinese, Canadian and Australian patent offices, as well as European opposition practice. He coordinates U.S. and foreign prosecution with the goal of obtaining the most effective and strongest coverage available, with a particular focus on the most lucrative markets. Dr. Amos is also an approved IP legal services vendor for NIH’s TABA program.
Dr. Amos received a Ph.D. in Neuroscience from the RFHSM, part of University College London which is consistently ranked among the world’s top universities, and graduated magna cum laude from New York Law School. He is admitted to the New York State Bar and is registered to practice before the U.S. Patent and Trademark Office.